Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax for Advanced Cutaneous T Cell Lymphoma
NCT04171791Phase 1Completed
- Sponsor
- Yale University
- Start
- Jan 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in cutaneous T-cell lymphoma (CTCL), sponsored by Yale University. Primary endpoints: Body Temperature up to 32 weeks, Blood Pressure- Diastolic up to 32 weeks and 4 more. Started Jan 2020; status: completed.
02
Drugs
venetoclax
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT04171791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171791.